Levofloxacin Actavis 5 mg/ml Ögondroppar, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

levofloxacin actavis 5 mg/ml ögondroppar, lösning

actavis group ptc ehf. - levofloxacinhemihydrat - Ögondroppar, lösning - 5 mg/ml - bensalkoniumklorid hjälpämne; levofloxacinhemihydrat 5,12 mg aktiv substans

Pipexus 2,1 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pipexus 2,1 mg depottablett

ethypharm sa - pramipexoldihydrokloridmonohydrat - depottablett - 2,1 mg - pramipexoldihydrokloridmonohydrat 3 mg aktiv substans

Pipexus 1,57 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pipexus 1,57 mg depottablett

ethypharm sa - pramipexoldihydrokloridmonohydrat - depottablett - 1,57 mg - pramipexoldihydrokloridmonohydrat 2,25 mg aktiv substans

Pipexus 0,26 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pipexus 0,26 mg depottablett

ethypharm sa - pramipexoldihydrokloridmonohydrat - depottablett - 0,26 mg - pramipexoldihydrokloridmonohydrat 0,375 mg aktiv substans

Pipexus 0,52 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pipexus 0,52 mg depottablett

ethypharm sa - pramipexoldihydrokloridmonohydrat - depottablett - 0,52 mg - pramipexoldihydrokloridmonohydrat 0,75 mg aktiv substans

Pipexus 1,05 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pipexus 1,05 mg depottablett

ethypharm sa - pramipexoldihydrokloridmonohydrat - depottablett - 1,05 mg - pramipexoldihydrokloridmonohydrat 1,5 mg aktiv substans

Pipexus 2,62 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pipexus 2,62 mg depottablett

ethypharm sa - pramipexoldihydrokloridmonohydrat - depottablett - 2,62 mg - pramipexoldihydrokloridmonohydrat 3,75 mg aktiv substans

Pipexus 3,15 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pipexus 3,15 mg depottablett

ethypharm sa - pramipexoldihydrokloridmonohydrat - depottablett - 3,15 mg - pramipexoldihydrokloridmonohydrat 4,5 mg aktiv substans

Pramipexole Orion 1,57 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pramipexole orion 1,57 mg depottablett

orion corporation - pramipexoldihydrokloridmonohydrat - depottablett - 1,57 mg - pramipexoldihydrokloridmonohydrat 2,25 mg aktiv substans

Sitagliptin / Metformin hydrochloride Mylan Europeiska unionen - svenska - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.